WO2021125910A3 - Pharmaceutical composition for preventing or treating cancer, comprising ndpk activator and h-prune inhibitor - Google Patents

Pharmaceutical composition for preventing or treating cancer, comprising ndpk activator and h-prune inhibitor Download PDF

Info

Publication number
WO2021125910A3
WO2021125910A3 PCT/KR2020/018757 KR2020018757W WO2021125910A3 WO 2021125910 A3 WO2021125910 A3 WO 2021125910A3 KR 2020018757 W KR2020018757 W KR 2020018757W WO 2021125910 A3 WO2021125910 A3 WO 2021125910A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
treating cancer
preventing
ndpk
prune
Prior art date
Application number
PCT/KR2020/018757
Other languages
French (fr)
Korean (ko)
Other versions
WO2021125910A2 (en
Inventor
김홍렬
임혁순
Original Assignee
주식회사 하임네이처
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 하임네이처 filed Critical 주식회사 하임네이처
Publication of WO2021125910A2 publication Critical patent/WO2021125910A2/en
Publication of WO2021125910A3 publication Critical patent/WO2021125910A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a co-administration pharmaceutical composition for effectively preventing or treating cancer. The pharmaceutical composition of the present invention can be applied to various cancer and, during co-administration, has a cancer cell killing effect remarkably improved over that of a single administration, and thus wide use of the composition for cancer treatment in the medical and healthcare fields is expected.
PCT/KR2020/018757 2019-12-20 2020-12-21 Pharmaceutical composition for preventing or treating cancer, comprising ndpk activator and h-prune inhibitor WO2021125910A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190171772A KR102442998B1 (en) 2019-12-20 2019-12-20 A pharmaceutical composition comprising NDPK activator and H-prune inhibitor for treating cancer)
KR10-2019-0171772 2019-12-20

Publications (2)

Publication Number Publication Date
WO2021125910A2 WO2021125910A2 (en) 2021-06-24
WO2021125910A3 true WO2021125910A3 (en) 2021-08-05

Family

ID=76478488

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/018757 WO2021125910A2 (en) 2019-12-20 2020-12-21 Pharmaceutical composition for preventing or treating cancer, comprising ndpk activator and h-prune inhibitor

Country Status (2)

Country Link
KR (1) KR102442998B1 (en)
WO (1) WO2021125910A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180121415A (en) * 2017-04-28 2018-11-07 이화여자대학교 산학협력단 A pharmaceutical composition comprising Nm23 activator for anti-metastasis
KR20190136425A (en) * 2018-05-30 2019-12-10 이화여자대학교 산학협력단 Novel biphenyl derivative compound and use thereof
KR20190136439A (en) * 2018-05-30 2019-12-10 이화여자대학교 산학협력단 Novel biphenyl derivative compound and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180121415A (en) * 2017-04-28 2018-11-07 이화여자대학교 산학협력단 A pharmaceutical composition comprising Nm23 activator for anti-metastasis
KR20190136425A (en) * 2018-05-30 2019-12-10 이화여자대학교 산학협력단 Novel biphenyl derivative compound and use thereof
KR20190136439A (en) * 2018-05-30 2019-12-10 이화여자대학교 산학협력단 Novel biphenyl derivative compound and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANGELO A D, ET AL.: "Prune cAMP phosphodiesterase binds nm23-HI and promotes cancer metastasis", CANCER CELL, CELL PRESS, US, vol. 5, no. 2, 1 February 2004 (2004-02-01), US, pages 137 - 149, XP003026537, ISSN: 1535-6108 *
LEE JAE-JIN, KIM HWANG SUK, LEE JI-SUN, PARK JIMIN, SHIN SANG CHUL, SONG SOONWHA, LEE EUNSUN, CHOI JUNG-EUN, SUH JI-WAN, LEE HONGS: "Small molecule activator of Nm23/NDPK as an inhibitor of metastasis", SCIENTIFIC REPORTS, vol. 8, no. 1, 1 December 2018 (2018-12-01), pages 1 - 13, XP055818077, DOI: 10.1038/s41598-018-29101-6 *

Also Published As

Publication number Publication date
WO2021125910A2 (en) 2021-06-24
KR20210079712A (en) 2021-06-30
KR102442998B1 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
MX2020008258A (en) Pediatric niraparib formulations and pediatric treatment methods.
MX2021004431A (en) Novel processes.
WO2021050953A8 (en) Compositions and methods for the delivery of therapeutic biologics for treatment of disease
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2021001807A (en) Combination of histone deacetylase inhibitor and protein kinase inhibitor and pharmaceutical use thereof.
WO2014144130A3 (en) Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof
MX2019012884A (en) Combination therapy.
WO2020102804A3 (en) Pharmaceutical combination for treatment of cancer
WO2010030180A3 (en) Peptide formulations and uses thereof
WO2022238565A3 (en) Modulators of sortilin activity
WO2018102687A3 (en) Combination therapy for treating cancer
WO2020076760A3 (en) Sphingoid compounds for use in the prophylaxis and/or therapy of a viral infection
SG11201908234WA (en) Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer
ZA202300259B (en) Compound for the treatment of coronaviral infections
MX2023009520A (en) 4-aminoquinazoline compounds.
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
WO2015035410A8 (en) Cancer therapy
MX2023007080A (en) Method for treating fibrosis.
WO2021046315A3 (en) Inhibitors of encephalitic alphaviruses
HRP20230300T1 (en) Combinations of imetelstat and venetoclax for the treatment of acute myeloid leukaemia
EP4203943A4 (en) 1,2,4-trioxane compounds and compositions comprising the same for use in the prevention and treatment of cancer
MX2022005388A (en) Pyrrolidine and piperidine compounds.
MX2020001254A (en) Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor.
WO2021125910A3 (en) Pharmaceutical composition for preventing or treating cancer, comprising ndpk activator and h-prune inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20903720

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20903720

Country of ref document: EP

Kind code of ref document: A2